Venous Thromboembolism Treatment Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

Venous Thromboembolism Treatment Devices Market by Product (Compression System, Thrombectomy Systems, Inferior Vena Cava Filter, and Others), Disease Type (Deep Vein Thrombosis and Pulmonary Embolism), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Rest of the World) is expected to advance at a respectable CAGR forecast till 2032 owing to the increasing incidence of deep vein thrombosis and pulmonary embolism, increasing surgical procedures and hospitalizations due to increasing cancer prevalence and other chronic disorders, and rising product developmental activities among the key market players globally.

The venous thromboembolism treatment devices market is estimated to grow at a CAGR of 8.31% during the forecast period from 2025 to 2032. The overall market for venous thromboembolism (VTE) treatment devices is witnessing substantial growth due to several converging factors. The increasing incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE), driven by aging populations, sedentary lifestyles, and chronic illnesses, is significantly boosting demand for effective treatment solutions. Rising numbers of surgical procedures and hospitalizations elevate the risk of VTE, necessitating preventive and therapeutic devices. Additionally, the growing prevalence of cancer, an established risk factor for thromboembolic events, further amplifies the need for advanced VTE treatment. Coupled with this, continuous product development and innovation by key market players are enhancing the effectiveness and accessibility of VTE devices, collectively propelling market growth during the forecast period from 2025 to 2032.

Venous Thromboembolism Treatment Devices Market Dynamics:

According to the data provided by Thrombosis UK (2023), nearly 55%-60% of venous thromboembolism cases occur during or following hospitalization in the UK.

Additionally, as per the data provided by the NSW Government Organization (2023), approximately 14,000 Australians develop a venous thromboembolism each year. Venous thromboembolism is a serious and potentially life-threatening medical condition that occurs when a blood clot forms in a vein. This clinical urgency is fueling the adoption of advanced VTE treatment devices such as inferior vena cava (IVC) filters, mechanical thrombectomy devices, aspiration systems, and catheter-directed thrombolysis technologies, which offer minimally invasive alternatives to traditional anticoagulation therapy. These devices not only provide targeted clot removal and reduced recovery time but also minimize complications, making them increasingly preferred in emergency and interventional settings.

According to data provided by the World Health Organization in 2024, the International Agency for Research on Cancer (IARC) stated that 20 million new instances of cancer were registered in 2022 globally.

Additionally, according to the data provided by the World Health Organization (2023), globally, over 15 million people were living with spinal cord injury. Patients undergoing spinal surgeries often experience prolonged immobility, reduced muscle activity, and vascular trauma, all of which contribute to blood stasis and increase the likelihood of deep vein thrombosis and pulmonary embolism. Similarly, cancer patients are predisposed to a hypercoagulable state due to malignancy-related inflammation, tumor-secreted procoagulant factors, and chemotherapy side effects, making VTE one of the leading complications in oncology care. Chronic disorders such as heart failure, chronic kidney disease, inflammatory bowel disease, and autoimmune conditions further raise the risk of VTE through persistent systemic inflammation, endothelial dysfunction, and reduced mobility, thereby boosting the overall market of venous thromboembolism treatment devices.

Moreover, the increased product developmental activities among key market players across the globe are further expected to drive the market growth for venous thromboembolism treatment devices. For example, in September 2024, Argon Medical introduced a new thrombectomy system, the CLEANER Vac, which provided doctors with manual control over suction, ensuring precise clot removal.

Therefore, the factors stated above collectively will drive the overall venous thromboembolism treatment devices market during the forecast period from 2025 to 2032.

However, the risk and complications associated with these devices, availability of alternative treatment options, and others may limit their end-user base, thus acting as key constraints limiting the growth of the venous thromboembolism treatment devices.

Venous Thromboembolism Treatment Devices Market Segment Analysis:

Venous Thromboembolism Treatment Devices Market by Product (Compression System, Thrombectomy Systems, Inferior Vena Cava Filter, and Others), Disease Type (Deep Vein Thrombosis and Pulmonary Embolism), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Rest of the World)

In the product segment of the venous thromboembolism treatment devices market, the compression system category is expected to amass a significant revenue share in the year 2024. This can be ascribed to the applications and advantages related to the category. Compression systems are playing a pivotal role in boosting the overall market of venous thromboembolism (VTE) treatment devices by offering an effective, non-invasive, and widely accessible method for the prevention and management of deep vein thrombosis (DVT), particularly in high-risk patient populations. These systems, which include graduated compression stockings (GCS) and intermittent pneumatic compression (IPC) devices, are increasingly adopted across hospitals, ambulatory surgical centers, and home healthcare settings due to their proven ability to enhance venous blood flow, reduce venous stasis, and prevent clot formation.

Their utility is particularly critical in post-operative care, especially following orthopedic, spinal, cancer, and cardiovascular surgery scenarios where patients often experience reduced mobility and an increased risk of thrombus formation. Compression systems are also widely used in non-surgical chronic conditions, such as stroke, heart failure, and paralysis, further expanding their market reach. With rising awareness about the risks of hospital-acquired VTE, healthcare facilities are integrating these systems into standard VTE prophylaxis protocols, thereby driving steady demand.

Technological advancements, such as the development of smart wearable compression devices with pressure monitoring and patient compliance tracking features, are making these systems more user-friendly and clinically efficient. Furthermore, the increase in product development activities among the key market players is further boosting the overall market of compression systems. For instance, in January 2025, a China-based manufacturer received 510(k) clearance from the U.S. FDA for its Venera 608 Deep Vein Thrombosis Prevention System, an intermittent pneumatic compression (IPC) device designed for calf, calf-thigh, and foot use. The system mimics natural walking to enhance circulation and comes with soft inflation sleeves.

Thus, the factors mentioned above are expected to boost the overall market of the segment, thereby escalating the overall market of venous thromboembolism.

North America is expected to dominate the overall venous thromboembolism treatment devices market:

Among all the regions, North America is expected to dominate the venous thromboembolism treatment devices market in the year 2024. This can be attributed to several factors such as the rising cancer cases, venous thromboembolism, and other chronic conditions, combined with significant advancements in product development & regulatory approvals. Additionally, the presence of well-established and sophisticated infrastructure is expected to drive the market for venous thromboembolism treatment devices during the forecast period from 2025 to 2032.

According to data from the Centers for Disease Control and Prevention (2025), stated that one-third (about 33%) of people were suffering from deep vein thrombosis (DVT) or pulmonary embolism (PE) in the US and may have a recurrence of the disease within 10 years.

The surge in these conditions is largely attributed to risk factors such as aging populations, sedentary lifestyles, obesity, cancer, orthopedic surgeries, and long-term immobility, especially in hospitalized or post-operative patients. This rise in DVT and PE cases is prompting urgent clinical demand for effective, timely, and safe treatment interventions. As a result, healthcare providers are increasingly adopting advanced VTE treatment devices, including inferior vena cava (IVC) filters, catheter-directed thrombolysis systems, mechanical and aspiration thrombectomy devices, and intermittent pneumatic compression (IPC) systems. These devices provide critical solutions to either prevent clot formation, break down existing clots, or prevent embolization to the lungs, thereby boosting the overall market of venous thromboembolism treatment devices across the region.

Additionally, according to Global Cancer Observatory's data (2024), in 2022, the US represented 89.1% of all cancer cases, and Canada represented 10.9% of all cancer cases in the region. The high incidence of cancer and its associated hypercoagulability, along with a significant recurrence rate of venous thromboembolism, are driving the demand for venous thromboembolism treatment devices. These devices address critical complications in cancer patients, enhancing long-term management and outcomes.

Additionally, the increase in product development activities among the key market players is further boosting the overall market of venous thromboembolism treatment devices. For instance, in November 2024, Cardinal Health launched the Kendall SCD SmartFlow compression system, which delivers an all-in-one solution for deep vein thrombosis and pulmonary embolism prevention

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American region in the venous thromboembolism treatment devices market.

Venous Thromboembolism Treatment Devices Market key players:

Some of the key market players operating in the venous thromboembolism treatment devices market include Abbott, Boston Scientific Corporation, AngioDynamics, Argon Medical Devices, Penumbra, Inc., Thrombolex, Imperative Care Inc., Koninklijke Philips N.V., Arjo, Stryker, Cook, BIOCOMPRESSION SYSTEMS, Medtronic, DSMAREF CO., LTD., Teleflex Incorporated, Surmodics Inc., ICE Aspiration System, VentiV Scientific, Inquis Medical, Cardinal Health, and others.

Recent Developmental Activities in the Venous Thromboembolism Treatment Devices Market:

• In October 2024, Surmodics Inc. announced it had received FDA 510(k) clearance for its Pounce XL thrombectomy system.
• In April 2024, the ICE Aspiration System received FDA 510(k) clearance for the Expanse ICE Aspiration System.
• In January 2023, Inari Medical enrolled the first participant in the DEFIANCE trial of its ClotTriever System in iliofemoral deep vein thrombosis (DVT) patients.

Key takeaways from the venous thromboembolism treatment devices market report study

• Market size analysis for current venous thromboembolism treatment devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the venous thromboembolism treatment devices market
• Various opportunities available for the other competitors in the venous thromboembolism treatment devices market space
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current venous thromboembolism treatment devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the venous thromboembolism treatment devices market growth in the future?

Target audience who can benefit from this venous thromboembolism treatment devices market report study

• Venous thromboembolism treatment devices product providers
• Research organizations and consulting companies
• Venous thromboembolism treatment devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in venous thromboembolism treatment devices
• Various end-users who want to know more about the venous thromboembolism treatment devices market and the latest developments in the venous thromboembolism treatment devices market

Frequently Asked Questions for the Venous Thromboembolism Treatment Devices Market:

1. What are venous thromboembolism treatment devices?

• The venous thromboembolism can be defined as the clotting of blood in the veins, which is an undiagnosed and serious, yet preventable condition that can cause disability and death. Venous thromboembolism treatment devices are devices that can be either implanted or inserted into the body to treat embolism.

2. What is the market for venous thromboembolism treatment devices?

• The venous thromboembolism treatment devices market is estimated to grow at a CAGR of 8.31% during the forecast period from 2025 to 2032.

3. What are the drivers for the venous thromboembolism treatment devices market?

• The overall market for venous thromboembolism (VTE) treatment devices is witnessing substantial growth due to several converging factors. The increasing incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE), driven by aging populations, sedentary lifestyles, and chronic illnesses, is significantly boosting demand for effective treatment solutions. Rising numbers of surgical procedures and hospitalizations elevate the risk of VTE, necessitating preventive and therapeutic devices. Additionally, the growing prevalence of cancer, an established risk factor for thromboembolic events, further amplifies the need for advanced VTE treatment. Coupled with this, continuous product development and innovation by key market players are enhancing the effectiveness and accessibility of VTE devices, collectively propelling market growth during the forecast period from 2025 to 2032.

4. Who are the key players operating in the venous thromboembolism treatment devices market?

• Some of the key market players operating in the venous thromboembolism treatment devices market include Abbott, Boston Scientific Corporation, AngioDynamics, Argon Medical Devices, Penumbra, Inc., Thrombolex, Imperative Care Inc., Koninklijke Philips N.V., Arjo, Stryker, Cook, BIOCOMPRESSION SYSTEMS, Medtronic, DSMAREF CO., LTD., Teleflex Incorporated, Surmodics Inc., ICE Aspiration System, VentiV Scientific, Inquis Medical, Cardinal Health, and others.

5. Which region has the highest share in the venous thromboembolism treatment devices market?

• Among all the regions, North America is estimated to hold a significant revenue share in the venous thromboembolism treatment devices market in 2024. This can be attributed to several factors, such as the rising cancer cases, venous thromboembolism, combined with significant advancements in product development & regulatory approvals. Additionally, the presence of well-established and sophisticated infrastructure is expected to drive the market for venous thromboembolism treatment devices during the forecast period from 2025 to 2032.